Stocks of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) traded higher last session on Wall Street, down -0.62% to $0.21.
According to the data, Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) has 2 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $0.21, this indicates a potential upside of 3233.33 percent. PIRS stock price is now -65.94% away from the 50-day moving average and -79.64% away from the 200-day moving average. The market capitalization of the company currently stands at $17.71M.
A total of 1 analysts have issued a hold rating and 1 have given it a buy rating. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target maintained at $5, Robert W. Baird recently Upgraded its rating from Neutral to Outperform for Pieris Pharmaceuticals Inc. (NASDAQ: PIRS).
In other news, KIRITSY CHRISTOPHER P, Director bought 10,000 shares of the company’s stock on May 25. The stock was bought for $8,500 at an average price of $0.85. Upon completion of the transaction, the Director now directly owns 20,000 shares in the company, valued at $4200.0. A total of 9.85% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PIRS stock. A new stake in Pieris Pharmaceuticals Inc. shares was purchased by BANK OF MONTREAL /CAN/ during the first quarter worth $100,000. WALLEYE CAPITAL LLC invested $100,000 in shares of PIRS during the first quarter. In the first quarter, AFFINITY ASSET ADVISORS, LLC acquired a new stake in Pieris Pharmaceuticals Inc. valued at approximately $64,000. OCTAGON CAPITAL ADVISORS LP acquired a new stake in PIRS for approximately $63,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in PIRS valued at around $3,000 in the second quarter. In total, there are 74 active investors with 55.40% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $0.2190 for Pieris Pharmaceuticals Inc. (NASDAQ: PIRS). During the past 12 months, Pieris Pharmaceuticals Inc. has had a low of $0.16 and a high of $1.98. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.40, and a quick ratio of 1.40. The fifty day moving average price for PIRS is $0.5977 and a two-hundred day moving average price translates $1.0171 for the stock.
The latest earnings results from Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of -$0.14 by -0.04. This compares to -$0.07 EPS in the same period last year. The company reported revenue of $1.94 million for the quarter, compared to $10.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -82.38 percent. For the current quarter, analysts expect PIRS to generate $4.02M in revenue.
Pieris Pharmaceuticals Inc.(PIRS) Company Profile
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
